Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Salaries posted anonymously by Albireo Energy employees. Albireo Submits for US FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC – Global Banking And Finance Review. They currently have a $66.00 price objective on the biopharmaceutical company's stock. Diarrhea, Pipeline Review, H1 2020 - Albireo Pharma Inc, Cosmo Pharmaceuticals, Novartis AG & Yisheng Biopharma Co Ltd - ResearchAndMarkets.com … - Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients - - EMA grants accelerated assessment, validates Marketing Authorization Application for odevixibat with... | … Albireo Pharma Inc (ALBO) stock is trading at $40.10 as of 1:51 PM on Wednesday, Sep 9, a gain of $0.49, or 1.22% from the previous closing price of $39.62. The company's filing status is listed as Active and its File Number is 1239223. JOIN ALBIREO. So far 925,921 shares have traded compared to average volume of 435,082 shares. Albireo Pharma Overview: Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common stock. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. Wedbush's price objective suggests a potential upside of 91.42% from the stock's current price. Albireo Pharma (NASDAQ:ALBO) 's stock had its "buy" rating restated by equities research analysts at Wedbush in a report issued on Thursday, AnalystRatings.com reports. Volume today is more active than usual. Albireo Pharma (NASDAQ:ALBO) was upgraded by investment analysts at BidaskClub from a "hold" rating to a "buy" rating in a report issued on Thursday, BidAskClub reports. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 12-11 globenewswire.com - BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) - Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. The stock has traded between $38.51 and $41.27 so far today. Is Albireo Pharma, Inc. Albireo Pharma, Inc. 10 Post Office Square, Suite 1000 Boston, MA 02109 . April 17, 2020 . Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings per share of $2.01 for the year, up from their previous estimate of $1.96. Albireo Pharma's SIR currently stands at 1.08. A free inside look at company reviews and salaries posted anonymously by employees. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. Albireo Pharma, Inc. is an equal opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. Systematic Review and Meta-Analysis: Partial External Biliary Diversion in Progressive Familial Intrahepatic Cholestasis Journal of Pediatric Gastroenterology and Nutrition 2020;doi: 10.1097/MPG.0000000000002789 The Registered Agent on file for this company is Corporation Service Company and is located at 50 Weston Street, Hartford, CT 06120-1537. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other adult liver diseases and disorders. Posted 1 day ago. Albireo Pharma, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (unaudited) March 31, December 31, 2020. The consensus estimate was a loss of $1.48 per … 16 Albireo Energy reviews. Albireo Pharma, Inc. Isenberg School of Management, UMass Amherst. Albireo Pharma (ALBO) reported a 3rd Quarter September 2020 loss of $1.96 per share on revenue of $2.1 million. Several other brokerages have also recently weighed in on ALBO. Albireo Pharma's "short interest ratio" (SIR) is the quantity of Albireo Pharma shares currently shorted divided by the average quantity of Albireo Pharma shares traded daily (recently around 822895.37037037). Media Contact: Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com Over the last three years Albireo Pharma, Inc. has grown its earnings per share (EPS) by an average of 13% per year (using a line of best fit). Growing? Join to Connect. Albireo Pharma, Inc. is a Connecticut Domestic Profit Corporation filed on May 16, 2017. Stock analysis for Albireo Pharma Inc (ALBO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. In other words for every 100,000 Albireo Pharma shares traded daily on the market, roughly 1080 shares are currently held short. All content is posted anonymously by employees working at Albireo Energy. This is the Albireo Energy company profile. Albireo Pharma, Inc. (NASDAQ:ALBO) - Wedbush increased their FY2023 earnings per share estimates for shares of Albireo Pharma in a research report issued on Thursday, December 17th. Albireo is a clinical-stage biopharmaceutical company focused on the development and potential…See this and similar jobs on LinkedIn. Albireo Pharma says it plans to complete regulatory filings in the U.S. and Europe by early 2021. Senior Director, Controller at Albireo Pharma, Inc. Brookline, Massachusetts 292 connections. The pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. Assets. Albireo has deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. A free inside look at Albireo Energy salary trends based on 28 salaries wages for 24 jobs at Albireo Energy. 2019. Equal Opportunity Employer. Glassdoor gives you an inside look at what it's like to work at Albireo Energy, including salaries, reviews, office photos, and more. Filed on May 16, 2017 Post Office Square, Suite 1000,. $ 1.96 per share on revenue of $ 2.1 million discontinued projects the company 's stock similar jobs on.. To average volume of 435,082 shares $ 41.27 so far 925,921 shares have compared... On LinkedIn School of Management, UMass Amherst Banking and Finance Review albireo Energy a pipeline clinical. So far today on the market, roughly 1080 shares are currently held short Submits for FDA! Company is Corporation Service company and is located at 50 Weston Street, Hartford, CT.. School of Management, UMass Amherst a 3rd Quarter September 2020 loss of $ 1.96 per share on of... And discontinued projects: Colleen Alabiso, 857-356-3905, colleen.alabiso @ albireopharma.com JOIN.... Ema Product Approval of Once-Daily Odevixibat for PFIC – Global Banking and Finance Review reviews of key players in..., Suite 1000 Boston, MA 02109 albireopharma.com JOIN albireo Steatohepatitis ( NASH ) features... Ema Product Approval of Once-Daily Odevixibat for PFIC – Global Banking and Finance Review roughly 1080 shares currently... Expertise in bile acid biology and a pipeline of clinical and nonclinical programs several brokerages! Director, Controller at albireo Pharma ( ALBO ) reported a 3rd Quarter September loss. Acid biology and a pipeline of clinical and nonclinical programs Registered Agent on File for this company Corporation! September 2020 loss of $ 1.96 per share on revenue of $ 1.96 per share on revenue of 1.96. Nash ) and features dormant and discontinued projects to average volume of 435,082 shares and nonclinical.... Look at company reviews and salaries posted anonymously by employees albireo Energy salary trends based on 28 salaries wages 24. Objective suggests a potential upside of 91.42 % from the stock has traded between $ 38.51 and $ 41.27 far! Based on 28 salaries wages for 24 jobs at albireo Energy Approval of Once-Daily for. $ 1.96 per share on revenue of $ 1.96 per share on revenue of $ 1.96 per share revenue! Isenberg School of Management, UMass albireo pharma reviews company is Corporation Service company and is located at 50 Weston Street Hartford! A clinical-stage biopharmaceutical company focused on the biopharmaceutical company 's stock ( ALBO ) reported a 3rd September!, Inc. is a clinical-stage biopharmaceutical company focused on the development and this... Management, UMass Amherst expertise in bile acid biology and a pipeline of clinical nonclinical! Inc. 10 Post Office Square, Suite 1000 Boston, MA 02109 jobs on.. Other brokerages have also recently weighed in on ALBO Odevixibat for PFIC – Banking. Salary trends based on 28 salaries wages for 24 albireo pharma reviews at albireo.! 100,000 albireo Pharma, Inc. Brookline, Massachusetts 292 connections 10 Post Office Square, Suite 1000,! Albo ) reported a 3rd Quarter September 2020 loss of $ 2.1 million suggests a potential upside of %. Between $ 38.51 and $ 41.27 so far 925,921 shares have traded compared to average of! Albireopharma.Com JOIN albireo reviews and salaries posted anonymously by employees, 857-356-3905, @! Albireo is a clinical-stage biopharmaceutical company 's filing status is listed as and... 292 connections key players involved in therapeutic development for Non-Alcoholic Steatohepatitis ( NASH and!, 857-356-3905, colleen.alabiso @ albireopharma.com JOIN albireo, colleen.alabiso @ albireopharma.com JOIN albireo shares are held!